Navigation Links
Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
Date:2/5/2008

in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
(Date:7/10/2014)... to the International Atomic Energy Agency (IAEA) the ... acquiring sufficient quantities of plutonium or highly enriched ... device. The IAEA also notes that most cases ... which can be challenging to detect with most ... appearing this week in the Journal of ...
(Date:7/10/2014)... Using microscopic polymer light resonators that expand in ... Quantum Photonics Laboratory have developed new optical sensors ... Optical sensors are ideal for detecting trace gas ... lightweight nature, and immunity to electromagnetic interference. , ... before, the MIT team conceived an extremely sensitive, ...
(Date:7/10/2014)... Understanding the basis of psychiatric disorders has been extremely ... increase risk but are insufficient to cause disease. Now ... Cell Press journal Cell Stem Cell describe ... genetic risks interact with other risk factors or environmental ... Their research pinpoints a genetic variant that may predispose ...
Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Sensitive detection method may help impede illicit nuclear trafficking 2Swell new sensors 2New strategy could uncover genes at the root of psychiatric illnesses 2
... AMDL, Inc. (Amex:,ADL), with operations in Shenzhen, ... subsidiary Jade Pharmaceutical Inc. (JPI), an international,biopharma ... and,marketing of proprietary pharmaceutical and diagnostic products, ... expansion plans to increase,annualized sales in FY2008, ...
... Nov. 20 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of,Sangamo,s ZFP Therapeutic ... at 11:00 am (ET) on Wednesday, November 28,2007 at ... New York. The presentation will be webcast live ...
... FOLD ) today announced that John F. Crowley, ... at the Lazard Capital,Markets Fourth Annual Healthcare Conference in ... ET at The New York Palace Hotel. A ... available to all,interested parties through the Investors section of ...
Cached Biology Technology:AMDL Launches New JPGreen Business Strategy 2Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 3
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... The Mills Canyon fire started near the City of ... of local resources, the fire quickly grew to over ... cause of the fire is under investigation by the ... is working with existing local resources in developing fire ... Forest Service (USFS), Washington State Department of Natural Resources, ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3
... at Mount Sinai School of Medicine have discovered a ... and resistance to chemotherapy, and participate in tumor progression. ... tests for early cancer diagnosis, prognostic tests, and innovative ... Resistance to chemotherapy is a frequent ...
... The decision has been taken by the German government to ... The transition process is gaining impetus but much remains to ... wind energy is to be dramatically expanded not only ... still immense potential inland that remains to be tapped, such ...
... appreciate this fabric, which looks innocuous but in fact ... a microcontroller that detects warning signals emitted when the ... can be used to protect buildings, bank vaults, and ... parked overnight at truck stops are particularly vulnerable to ...
Cached Biology News:Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel' 2More accurate wind energy forecasts 2More accurate wind energy forecasts 3A smart fabric sets off the alarm 2A smart fabric sets off the alarm 3
...
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: